Abstract Number: 2172 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of Serum Levels of Anti-Transcriptional Intermediary Factor 1-γ Antibody in Patients with Dermatomyositis
Background/Purpose: Dermatomyositis (DM) is an autoimmune inflammatory disease characterized by skin eruptions and myositis, which is occasionally complicated by interstitial lung disease (ILD) or concomitant…Abstract Number: 854 • 2017 ACR/ARHP Annual Meeting
Predictive Modeling of Mortality in Polymyositis/Dermatomyositis Patients with Interstitial Lung Disease Based on Combination of Serum Myositis-Specific Autoantibodies and Conventional Biomarkers
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with polymyositis or dermatomyositis (PM/DM). Since clinical courses and outcomes…Abstract Number: 2173 • 2017 ACR/ARHP Annual Meeting
Characteristics Unique to MDA5 and Anti-Ro/SSA-52 Kda Dual Antibody Positive Patients with Inflammatory Myopathies
Background/Purpose: The anti-melanoma differentiation-associated gene 5 antibody (MDA5) was recently classified as a myositis-specific antibody (MSA), and has been associated with rapidly progressive interstitial lung…Abstract Number: 1732 • 2017 ACR/ARHP Annual Meeting
The Characteristic T-Cell Receptor-Mediated Signaling of Peripheral Blood T Cells in Dermatomyositis and Polymyositis
Background/Purpose: In dermatomyositis (DM) and polymyositis (PM), the characteristics of T cell expression in peripheral blood have been previously described; especially, decreased expression of interferon-γ…Abstract Number: 2613 • 2017 ACR/ARHP Annual Meeting
Antimalarial Drug Toxicities in Rheumatic Skin Disease Patients
Background/Purpose: Although existing evidence demonstrates the efficacy of antimalarials for rheumatic skin disease, the safety of these medications, and particularly quinacrine, remain debated. Quinacrine may…Abstract Number: 1801 • 2017 ACR/ARHP Annual Meeting
Quantifying Clinical and Economic Outcomes Associated with Chronic Corticosteroid Exposure in a US Population
Background/Purpose: Corticosteroids (CS) are commonly used for rheumatologic conditions, and known to cause systemic adverse events (AEs), particularly when used at high doses for prolonged…Abstract Number: 2130 • 2017 ACR/ARHP Annual Meeting
Joint Manifestations in Patients Diagnosed with Idiopathic Inflammatory Myopathy: Multicenter Registry on Inflammatory Myositis from the Rheumatology Society in Madrid, Spain
Background/Purpose: Idiopathic inflammatory myopathies (IIM) comprise a heterogeneous group of autoimmune conditions characterized by muscle non-suppurative inflammation, progressive muscle weakness and a variety of extra-muscular…Abstract Number: 2132 • 2017 ACR/ARHP Annual Meeting
Angiogenesis and VEGF-Expressing Cells Are Identified Predominantly in the Fascia Rather Than the Muscle in the Early Phase of Dermatomyositis
Background/Purpose: We previously showed that fasciitis is a frequent manifestation of the disease in dermatomyositis (DM) but not in polymyositis (PM) and that DM-associated fasciitis…Abstract Number: 28 • 2017 Pediatric Rheumatology Symposium
Dyslipidemia in Juvenile Dermatomyositis
Background/Purpose: Juvenile Dermatomyositis (JDM) is a multisystem pediatric autoimmune disease characterized by chronic inflammation of muscle and skin. Premature atherosclerosis is an important cause of…Abstract Number: 1376 • 2016 ACR/ARHP Annual Meeting
In Juvenile Dermatomyositis, Organ Damage Is Comparable after Median 13.5 and 21.5 Years Follow-up Time, Despite Sustained Disease Activity
Background/Purpose: All previous studies of disease outcome in juvenile dermatomyositis (JDM) patients have been based on retrospective data or cross sectional examination. We aimed to…Abstract Number: 1500 • 2016 ACR/ARHP Annual Meeting
Concomitant Development of Interstitial Pneumonia Associated with Dermatomyositis and Rheumatoid Arthritis
Background/Purpose: A few cases of the concomitant development of interstitial pneumonia associated with dermatomyositis (DM-IP) and rheumatoid arthritis (RA) have been reported mainly in Asia,…Abstract Number: 2103 • 2016 ACR/ARHP Annual Meeting
Peripheral Blood B Cells Are Expanded and Their Cytokine Expression Is Dysregulated in Juvenile Dermatomyositis
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare form of childhood autoimmune myositis that presents with proximal muscle weakness and heliotrope rash. B cells are strongly…Abstract Number: 2236 • 2016 ACR/ARHP Annual Meeting
Effects of Repository Corticotropin Injection on Medication Use in Patients with Rheumatologic Conditions: A Claims Data Study
Background/Purpose: Repository corticotropin injection (RCI) may produce anti-inflammatory and immune-modulatory effects. This study examined the demographics of those who used RCI and the trends in…Abstract Number: 2311 • 2016 ACR/ARHP Annual Meeting
Initial Predictors of Short-Term Poor Survival Rates in Patients with Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Background/Purpose: Polymyositis (PM)/dermatomyositis (DM) is a chronic inflammatory disorder that affects muscle, skin and lung in various degree, and interstitial lung disease (ILD) is a…Abstract Number: 2315 • 2016 ACR/ARHP Annual Meeting
The Effectiveness of Social Media in Recruiting for Rare Rheumatic Diseases
Background/Purpose: Clinical research is dependent on being able to recruit and enroll appropriate patients in sufficient numbers to make robust conclusions. For many diseases it…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 24
- Next Page »